Employees Retirement System of Texas Sells 12,789 Shares of Johnson & Johnson $JNJ

Employees Retirement System of Texas trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 35.4% in the fourth quarter, HoldingsChannel reports. The firm owned 23,345 shares of the company’s stock after selling 12,789 shares during the quarter. Employees Retirement System of Texas’ holdings in Johnson & Johnson were worth $4,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. boosted its position in Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 545.6% during the third quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock worth $716,657,000 after acquiring an additional 3,266,354 shares during the period. Amundi boosted its holdings in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company’s stock worth $2,512,719,000 after acquiring an additional 2,163,838 shares during the period. Marshall Wace LLP boosted its holdings in shares of Johnson & Johnson by 126.3% during the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock worth $664,575,000 after acquiring an additional 2,000,609 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Johnson & Johnson during the third quarter worth approximately $367,467,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Royal Bank Of Canada restated an “outperform” rating and set a $265.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 15th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Rothschild & Co Redburn boosted their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Finally, Daiwa Securities Group boosted their target price on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research report on Thursday, April 16th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Trading Up 0.5%

JNJ opened at $231.38 on Thursday. Johnson & Johnson has a twelve month low of $149.04 and a twelve month high of $251.71. The company has a 50-day simple moving average of $233.41 and a 200 day simple moving average of $224.50. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $556.97 billion, a price-to-earnings ratio of 26.75, a P/E/G ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced it will hold its second-quarter earnings conference call on July 15, reinforcing near-term focus on results, guidance, and management commentary. Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
• Positive Sentiment: DePuy Synthes, J&J’s orthopedic business, struck an exclusive distribution deal for the NOVOSIS bone graft product, adding another growth-oriented medtech move. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership
• Positive Sentiment: Market commentary highlighted J&J as one of several large-cap pharma stocks worth holding as the industry recovery accelerates, supporting sentiment toward the stock. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: J&J was reported to have an average brokerage recommendation of “Moderate Buy,” suggesting analysts remain constructive on the shares. Johnson & Johnson Receives Average Recommendation of Moderate Buy from Brokerages
• Neutral Sentiment: J&J also presented at Bernstein’s Strategic Decisions Conference, but the transcript does not point to a fresh, stock-moving surprise by itself. Johnson & Johnson Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
• Negative Sentiment: Talc litigation remains an overhang, with new verdict headlines reinforcing legal risk that could pressure valuation multiples. Assessing Johnson & Johnson Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with pharma and healthcare stocks described as a drag on the market in recent trading. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.